Shuanghuanglian big sale, which drug companies are involved in the big sale?

Novel coronavirus was found in January 31st by Xinhua news agency, which was informed by the Shanghai Institute of medicine, China Academy of Sciences The joint study of the Institute and the Wuhan virus initially found that the Chinese patent medicine Shuanghuanglian oral liquid could inhibit the new coronavirus The next day, the people's daily declared that "inhibition does not mean prevention and treatment! Do not panic buying novel coronavirus oral liquid, and emphasize that so far, there is no drug for preventing and treating new coronavirus But even if there is only one day, it still underestimates the action power of the Chinese people Only one night, Shuanghuanglian series of products in the major pharmacies have been looted Regardless of the opinions on popular science on the Internet, it can't stop the people running in the steps of the major pharmacies Even the manufacturers of Shuanghuanglian series products are not clear How could my medicine become the life-saving straw of "new pneumonia" overnight? I don't know? Similar to the hot performance of the concept stocks of "masks" before the Spring Festival and the recent US stocks related to "bio medicine", many investors believe that perhaps the enterprises related to "Shuanghuanglian oral liquid" will also face a new wave of uplift Photo source: intelligence data Among the above-mentioned companies, Henan Tailong Pharmaceutical Co., Ltd and Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd are all A-share listed companies, Harbin Pharmaceutical Group Sanjing Pharmaceutical Co., Ltd is a wholly-owned subsidiary of Harbin Pharmaceutical Co., Ltd., Henan Tiandi Pharmaceutical Co., Ltd is a controlling subsidiary of the listed company, and Henan Fushen Pharmaceutical Co., Ltd is a Hong Kong listed company The novel coronavirus data from Harbin hospital, the Sanqi oral liquid hospital, is reported by the daily report of the Harbin daily In January 23rd, Sanjing Shuanghuanglian oral liquid was formally incorporated into the new coronavirus control program by the Chinese medicine administration of the city Since the second day of the new year, the second plant of traditional Chinese medicine, Harbin Pharmaceutical Biology and Sanjing pharmacy under Harbin Pharmaceutical Group have started to work overtime to produce Sanjing Shuanghuanglian oral liquid, Qingre Jiedu oral liquid, thymus injection method and other drugs, and work with the people of the whole country to fight against the epidemic At the same time, the head of Harbin Pharmaceutical Group also said that he would continue to pay attention to the needs of drugs and materials to fight the epidemic, spare no effort to ensure the supply of drugs and urgently needed materials, overcome the difficulties, and win the battle against pneumonia Looking at the annual report of Harbin Pharmaceutical Co., Ltd in 2018, we can see that its production and sales volume are in the forefront of the industry In 2018, the production and sales volume reached 190 million and 190 million respectively, basically all of which are out of stock, and the inventory is only 3.03 million On January 22, Harbin Pharmaceutical Co., Ltd issued the 2019 annual performance reduction announcement The company's performance is expected to decrease by 270 million yuan to 310 million yuan, a year-on-year decrease of 78% to 90%; after deducting non recurring profit and loss events, the company's performance is expected to decrease by 255 million yuan to 295 million yuan, a year-on-year decrease of 104% to 121% It can be predicted that if the inventory is equal to that in 2018, according to the current situation of rush purchase, maybe the quality of Shuanghuanglian oral liquid of Harbin Pharmaceutical Co., Ltd will increase in 2019 In 2018, novel coronavirus oral liquid production and sales data were obtained from Harbin Pharmaceutical Company, the photo source: Harbin Pharmaceutical annual report of Tai Long pharmaceutical company, Tai Long pharmaceutical company as one of the leading manufacturers of Shuanghuanglian oral liquid in China The responsible person told E reporters that he himself had just learned that Shuanghuanglian could inhibit the news of the new coronavirus He also said that due to the impact of the epidemic and the increase of market demand, the company had ended the holiday to resume production on the third day of the lunar new year As for the issue of whether to increase production in the later stage, it said that it would organize a meeting as soon as possible to discuss According to the 2018 annual report of Talon Pharmaceutical Co., Ltd., although the production and sales volume are no less than Harbin Pharmaceutical Co., Ltd., they also reach 76.22 million and 65.8 million respectively Combined with a 20.79% rise since 2019, the company's profits may have been boosted by the double yellow fire yesterday Production and sales data of Shuanghuanglian oral liquid of Talon pharmaceutical in 2018 source: annual report of Talon pharmaceutical in 2018 In the announcement, it was revealed that the increase in sales of Shuanghuanglian oral liquid (children's type) and ordinary Shuanghuanglian oral liquid in 2018 was due to the 77.07% increase in inventory compared with that in 2017 If Tailong pharmaceutical industry can still adopt the strategy of centralized production in advance and increasing product reserve in 2019, perhaps "the biggest beneficiary of Shuanghuanglian fire" will be it Fu'an pharmaceutical, once known as "China's largest manufacturer of Shuanghuanglian cold medicine", was founded in November 2003 in Xichuan County, Henan Province It was founded on the basis of the original Henan Xichuan Pharmaceutical Group Co., Ltd after asset restructuring As the most important part of the revenue, Shuanghuanglian oral liquid and Shuanghuanglian injection play an important role In 2015, 2016 and the first three quarters of 2017, the sales of Shuanghuanglian drugs accounted for 79.6%, 81.6% and 75.8% of the revenue in the same period respectively According to the annual report of 2018, Shuanghuanglian oral liquid and injection produced by Fushen Pharmaceutical Co., Ltd accounted for 73.8% of its revenue, and 69.7% in the half year report of 2019, of which Shuanghuanglian oral liquid accounted for more than half of the company's revenue In 2019, compared with the level of Talon pharmaceutical industry, it is only 19.58% Perhaps this year's tepid Shuanghuanglian production revenue will pick up Photo source of sales volume of Shuanghuanglian oral liquid of Fuan pharmaceutical in 2018 With regard to the novel coronavirus problem caused by Shuanghuanglian, many netizens said that when the mask was sold out, the mask stocks rose, and the two yellow cops were out of stock If there were no accidents, Shuanghuanglian stocks would also rise But in the current epidemic situation, blindly following the trend is a big taboo Moreover, nowadays, the media public opinion is also guiding the misunderstanding of netizens I believe that after the fermentation of the last mask incident, people's panic about not being able to buy "Shuanghuanglian" will last for a while As a country, we should stand up in time to stop rumors and false news As a large number of people, we should follow the trend blindly, or we will regret later Data source: Pharmaceutical intelligence data, enterprise annual report, e company reporter report, Harbin Daily report and other responsible editors | penicillin statement: this point of view only represents the author, not the position of pharmaceutical intelligence network, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.